Compare Ascendis Pharma A/S (ASND) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs KLA Corp. — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while KLA Corp. trades at $208.6 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 15.7× Ascendis Pharma A/S's market cap, and KLA Corp. pays a 0.46% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KLAC | |
|---|---|---|
Market Cap | $16.67B | $261.92B |
Sector | Health | Technology |
52-Week High | $277.18 | $301.71 |
52-Week Low | $189.74 | $84.39 |
Enterprise Value | $17.04B | $263.17B |
Dividend Yield | — | 0.46% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
